How much do you know about the female body? Your body? Or your friend's, your sister's, your daughter's? Oh, you know the one ...

The PGIM Jennison Health Sciences Fund lost value, underperforming its benchmark Index during the Q1 of 2025. Click here to ...

I am always on the hunt for ways to be a little more sustainable and cut out toxins from my home, and nowhere is this more prevalent than in my kitchen.That is why I quit using plastic wrap years ago ...

AACE released clinical guidelines on the diagnosis, management, and surveillance of tumors related to multiple endocrine neoplasia type 1.

Secondary forms of metabolic dysfunction-associated steatotic liver disease (MASLD) have different pathogeneses, ...

For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a neurokinin-targeted therapy, reduces the ...

We performed a phase 3 trial involving women 18 to 70 years of age with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer or its prevention ...

More than 46% of women with stage 1 or 2 breast cancer chose to continue endocrine therapy after five years, a recent study found. The study, published in the Journal of the National Cancer Institute, ...

Findings seen in women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer.

The mean change from baseline in the mean daily frequency of moderate-to-severe vasomotor symptoms at week 4 was −6.5 and −3.0 episodes for those receiving elinzanetant and placebo, respectively.

The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its prevention ...